Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Putative circulating adipose tissue-derived stem cells, obesity, and metabolic syndrome features.

Bonora BM., Cappellari R., Albiero M., Prevedello L., Foletto M., Vettor R.

Prospective Study with a reported sample of 111 on Type 2 Diabetes, published in J Endocrinol Invest (2023) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Endocrinol Invest (2023)
Country
Italy
Reported sample size
111
Source database
PubMed
PMID
36952215
PMCID
PMC10514150
DOI
10.1007/s40618-023-02067-7
Citations
1

Abstract (original English)

In mice, adipose tissue-derived stem cells (ASCs) reach the systemic circulation and establish ectopic adipose depots fostering insulin resistance, but whether this occurs in humans is unknown. We examined circulating ASCs in individuals with various combination of metabolic syndrome traits. We enrolled patients attending a routine metabolic evaluation or scheduled for bariatric surgery. We quantified ASCs as CD34 + CD45 - CD31 - (CD36 + ) cells in the stromal vascular fraction of subcutaneous and visceral adipose tissue samples and examined the presence and frequency of putative ASCs in peripheral blood. We included 111 patients (mean age 59 years, 55% males), 40 of whom were scheduled for bariatric surgery. The population of CD34 + CD45 - CD31 - ASCs was significantly more frequent in visceral than subcutaneous adipose depots (10.4 vs 4.1% of the stromal vascular fraction; p < 0.001), but not correlated with BMI or metabolic syndrome traits. The same phenotype of ASCs was detectable in peripheral blood of 58.6% of patients. Those with detectable circulating ASCs had significantly higher BMI (37.8 vs 33.3 kg/m 2 ; p = 0.003) and waist (111.2 vs 105.4 cm; p = 0.001), but no difference in other metabolic syndrome traits (p = 0.84). After bariatric surgery, patients with detectable circulating ASCs had greater BMI reductions at 6 months (- 10.4 vs - 7.8 kg/m 2 ; p = 0.014). Prese

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
MaleHumansMiceAnimalsMiddle AgedFemaleMetabolic SyndromeObesityAdipose TissueStem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research